- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06502691
[18F] Tomografía por emisión de positrones FTT para medir la expresión tumoral de PARP en pacientes con cáncer de mama metastásico
[18F] Tomografía por emisión de positrones (PET) FTT en pacientes con cáncer de mama metastásico
This clinical trial studies how well fluorine F 18 fluorthanatrace ([18F]FTT) positron emission tomography (PET) works in imaging patients with breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) who are receiving standard of care (SOC) poly (ADP-ribose) polymerase (PARP) inhibitors with or without immune checkpoint inhibitors (ICI) to be able to detect clinical response to PARP inhibitor ± ICI treatment. [18F]FTT is a radiotracer that targets and binds to PARP1 which can potentially be used for the imaging of PARP1 expression using PET. Once administered, [18F]FTT targets and binds to PARP1. Upon PET, PARP1-expressing tumor cells can be visualized. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case, [18F]FTT. Because some cancers take up [18F]FTT it can be seen with PET. PARP inhibitors work as a targeted therapy by blocking an enzyme involved in repairing cell damage. It may cause tumor cells to die. ICI may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Combining [18F]FTT with a PET scan may help detect tumor cells better in patients with metastatic breast cancer who are receiving standard of care PARP inhibitors with our without ICI treatment.
Descripción general del estudio
Estado
Intervención / Tratamiento
- Otro: Electronic Health Record Review
- Otro: Fludeoxyglucose F-18
- Radiación: Fluorine F 18 Fluorthanatrace
- Procedimiento: Computed Tomography
- Procedimiento: Positron Emission Tomography
- Otro: Best Practice
- Procedimiento: Biopsy of Breast
- Droga: Immune Checkpoint Inhibitor
- Droga: Poly (ADP-Ribose) Polymerase Inhibitor
- Procedimiento: Positron Emission Tomography
Descripción detallada
OUTLINE: Patients are assigned to 1 of 2 arms.
Arm I: Patients receive [18F]FTT intravenously (IV) and undergo PET scan 60-75 minutes later on day 1 of initiating SOC PARP inhibitor ± ICI therapy and again at 12 weeks. At least 1-7 days later, patients undergo SOC FDG PET/computed tomography (CT) and follow up scans at 12 weeks and 6 months. Patients may also undergo tissue biopsy during screening and during follow up.
Arm II: Patients receive [18F]FTT IV and undergo PET scan 60-75 minutes later on day 1 of initiating SOC PARP inhibitor ± ICI therapy. At least 1-7 days later, patients undergo SOC FDG PET/CT and follow up scans at 12 weeks and 6 months. Patients may also undergo tissue biopsy during screening.
After initial [18F]FTT PET imaging, patients are followed-up to 6 months or until disease progression.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jennifer Specht, MD
- Número de teléfono: 206-606-6889
- Correo electrónico: jspecht@uw.edu
Ubicaciones de estudio
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- Fred Hutch/University of Washington Cancer Consortium
-
Investigador principal:
- Jennifer Specht, MD
-
Contacto:
- Jennifer Specht, MD
- Número de teléfono: 206-606-6889
- Correo electrónico: jspecht@uw.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients must have histologically confirmed invasive breast cancer with metastatic disease
- Patients must be candidates for treatment with PARP inhibitor as a single agent or for PARP inhibitor in combination with an ICI per treating physician discretion
- Patients must have evaluable disease or at least one measurable lesion that can be assessed at baseline by CT (or magnetic resonance imaging [MRI]) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Age >= 18 years
- Karnofsky performance status (KPS) >= 50% or Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Archival tissue (formalin-fixed paraffin-embedded [FFPE]) from at least one metastatic site biopsy should be available prior to study enrollment; if archival tissue is not available, then a metastatic site biopsy will be required during the study screening period
- Patient must be willing to proceed with an on-treatment biopsy of metastatic site if an on-treatment [18F]FTT PET will be performed (at 12 ± 4 weeks after starting PARP inhibitor ± ICI treatment)
- For women of childbearing potential, a negative serum pregnancy test is required within 7 days prior to [18F]FTT PET imaging on day 1. For women who obtain on-treatment (12-week) [18F]FTT imaging, a negative serum pregnancy test will be required within 7 days prior to [18F]FTT PET imaging
- Men and women of reproductive potential need to agree to employ two highly effective and acceptable forms of contraception throughout their participation in the study
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
- Ability to understand and the willingness to sign a written informed consent document. Informed consent must be provided prior to any study specific procedures
Exclusion Criteria:
- Patients with prior myelodysplastic syndrome or acute myeloid leukemia due to rare risk associated with PARP inhibitor therapy
- Pregnant or breastfeeding women
- Patient with a known hypersensitivity to the proposed PARP inhibitor product
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of PARP inhibitor therapy (per investigator's discretion)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm I ([18F]FTT PET, FDG PET/CT, PARP inhibitor, ICI)
Patients receive [18F]FTT IV and undergo PET scan 60-75 minutes later on day 1 of initiating SOC PARP inhibitor ± ICI therapy and again at 12 weeks. At least 1-7 days later, patients undergo SOC FDG PET/CT and follow up scans at 12 weeks and 6 months. Patients may also undergo tissue biopsy during screening and during follow up. |
Ancillary studies Given FDG
Otros nombres:
Given IV
Otros nombres:
Undergo FDG PET/CT
Otros nombres:
Undergo FDG PET/CT
Otros nombres:
Receive of standard care
Otros nombres:
Undergo breast biopsy
Otros nombres:
Receive ICI treatment
Otros nombres:
Receive PARP inhibitor treatment
Otros nombres:
Undergo [18F]FTT PET
Otros nombres:
|
|
Comparador activo: Arm II ([18F]FTT PET, FDG PET/CT, PARP inhibitor, ICI)
Patients receive [18F]FTT IV and undergo PET scan 60-75 minutes later on day 1 of initiating SOC PARP inhibitor ± ICI therapy. At least 1-7 days later, patients undergo SOC FDG PET/CT and follow up scans at 12 weeks and 6 months. Patients may also undergo tissue biopsy during screening. |
Ancillary studies Given FDG
Otros nombres:
Given IV
Otros nombres:
Undergo FDG PET/CT
Otros nombres:
Undergo FDG PET/CT
Otros nombres:
Receive of standard care
Otros nombres:
Undergo breast biopsy
Otros nombres:
Receive ICI treatment
Otros nombres:
Receive PARP inhibitor treatment
Otros nombres:
Undergo [18F]FTT PET
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall response rate (ORR)
Periodo de tiempo: Baseline up to 6 months
|
Will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on poly (ADP-ribose) polymerase (PARP) inhibitor ± immune checkpoint inhibitor (ICI) treatment. Will use a boxplot to illustrate the difference of standard uptake value (SUV)max and SUVmean between responders and non-responders. |
Baseline up to 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
ORR
Periodo de tiempo: Baseline up to 6 months
|
Will be assessed using RECIST 1.1 criteria on PARP inhibitor ± ICI treatment. Will use the nonparametric method Wilcoxon Rank Sum test to evaluate the difference of the changes of SUVmax and/or SUVmean between responders and non-responders. |
Baseline up to 6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jennifer Specht, MD, Fred Hutch/University of Washington Cancer Consortium
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades de la piel
- Enfermedades de los senos
- Enfermedades de la piel y del tejido conectivo
- Neoplasias de mama
- Agentes antineoplásicos inmunológicos
- Agentes antineoplásicos
- Mecanismos moleculares de acción farmacológica.
- Inhibidores de enzimas
- Administración de Servicios de Salud
- Calidad, acceso y evaluación de la atención médica
- Técnicas de investigación
- Acciones farmacológicas
- Acciones y usos químicos
- Usos terapéuticos
- Calidad de la atención médica
- Carbohidratos
- Indicadores de calidad, atención médica
- Técnicas de química, analítica
- Análisis de espectro
- Desoxiglucosa
- Azúcares desoxi
- Pautas como tema
- Garantía de calidad, atención médica
- Inhibidores de puntos de control inmunitarios
- Inhibidores de poli(ADP-ribosa) polimerasa
- Fluorodesoxiglucosa F18
- Estándar de cuidado
- Espectroscopía de resonancia magnética
- Directrices de práctica como tema
Otros números de identificación del estudio
- RG1124440
- NCI-2024-04929 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- FHIRB0020495 (Otro identificador: Fred Hutch/University of Washington Cancer Consortium)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .